@article{larochelle_intolerance_2025,

title = {Intolerance of Uncertainty and Emotion Dysregulation as Predictors of Generalized Anxiety Disorder Severity in a Clinical Population},

author = {S. Larochelle and M. J. Dugas and F. Langlois and P. Gosselin and G. Belleville and S. Bouchard},

url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-86000587548&doi=10.3390%2fjcm14051502&partnerID=40&md5=ea6c43194a821d0a0623385714231936},

doi = {10.3390/jcm14051502},

issn = {20770383 (ISSN)},

year  = {2025},

date = {2025-01-01},

journal = {Journal of Clinical Medicine},

volume = {14},

number = {5},

abstract = {Background/objectives: Several factors have been shown to play a role in the development and maintenance of generalized anxiety disorder (GAD), including intolerance of uncertainty and emotion dysregulation. Although the individual contribution of both of these factors is well documented, their combined effect has yet to be studied in a clinical population with GAD. The aim of the present study was to examine the relative contribution of intolerance of uncertainty and emotion dysregulation to the prediction of worry and GAD severity in adults with GAD. Methods: The sample consisted of 108 participants diagnosed with GAD. The participants completed measures of worry, GAD severity, depressive symptoms, intolerance of uncertainty, and emotion dysregulation. Results: Multiple regression indicated that both intolerance of uncertainty and emotion dysregulation significantly contributed to both worry and GAD severity, over and above the contribution of depressive symptoms. Of note, the model explained 36% of the variance in GAD severity scores. Conclusions: The present results provide preliminary evidence of complementarity among dominant models of GAD, and point to the potential role of integrative conceptualizations and treatment strategies for GAD. © 2025 by the authors.},

note = {Publisher: Multidisciplinary Digital Publishing Institute (MDPI)},

keywords = {adult, aged, article, Beck Depression Inventory, clinical population, comorbidity, controlled study, Depression, difficulties in emotion regulation scale, disease severity, emotion, emotion dysregulation, emotion regulation, employment status, female, generalized anxiety disorder, human, intolerance of uncertainty, Intolerance of Uncertainty Scale, major clinical study, male, patient worry, penn state worry questionnaire, prediction, predictive model, psychotherapy, Severity of Illness Index, sociodemographics, theoretical model},

pubstate = {published},

tppubtype = {article}

}

@article{dugas_behavioral_2022,

title = {Behavioral Experiments for Intolerance of Uncertainty: A Randomized Clinical Trial for Adults With Generalized Anxiety Disorder},

author = {M. J. Dugas and K. A. Sexton and E. A. Hebert and S. Bouchard and J. -P. Gouin and R. Shafran},

url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85133178888&doi=10.1016%2fj.beth.2022.05.003&partnerID=40&md5=4dd15547cbef29c5f1adc84169176c53},

doi = {10.1016/j.beth.2022.05.003},

issn = {00057894 (ISSN)},

year  = {2022},

date = {2022-01-01},

journal = {Behavior Therapy},

volume = {53},

number = {6},

pages = {1147–1160},

abstract = {Sophisticated multicomponent treatments for adults with generalized anxiety disorder (GAD) have been developed over the past three decades. Although these comprehensive treatments have produced encouraging results, they appear to be less efficacious than treatments for other anxiety disorders. The goal of this randomized controlled trial is to test a newly developed, highly focused treatment for adults with GAD: Behavioral Experiments for Intolerance of Uncertainty. Sixty (60) participants (51 women, 9 men), with a mean age of 34.60 years (range: 19 to 67 years), were randomized to either treatment (n = 30) or wait-list control (n = 30). Treatment consisted of 12 weekly 1-hour sessions in which participants learned to use behavioral experiments to test their catastrophic beliefs about uncertainty. Assessments were conducted at pre-, mid- and postcondition, and at 6- and 12-month follow-up. The primary outcome was the severity of GAD, and secondary outcomes were worry, depression, somatic anxiety, and intolerance of uncertainty. Using growth curve modeling, we found that (1) the treatment group was superior to the wait-list group in terms of change from pre- to posttest on all outcomes; (2) the combined sample (once wait-listed participants received treatment) evidenced large and significant decreases on all outcomes; and (3) treatment gains were either maintained or increased over the 12-month follow-up period of the study. The new treatment is a promising treatment option for adults with GAD considering that it may be as efficacious as more comprehensive evidence-based psychological treatments for GAD. © 2022},

note = {Publisher: Elsevier Inc.},

keywords = {adult, aged, antidepressant agent, Anxiety, Anxiety disorder, Anxiety Disorders, anxiolytic agent, article, behavior assessment, behavioral experiments, benzodiazepine, cognitive behavioral therapy, cognitive vulnerability, Cognitive-behavioral treatment, confusion (uncertainty), controlled study, dependent variable, Depression, disease severity, female, follow up, generalized anxiety disorder, growth curve, human, Humans, intolerance of uncertainty, major clinical study, male, mental disease, outcome assessment, patient worry, procedures, psychology, randomized controlled trial, uncertainty},

pubstate = {published},

tppubtype = {article}

}